The first question about Cryo T-Shock is a regulatory one. Is it cleared to do what it is being sold to do? The FDA's 510(k) database returns no clearance under the device name Cryo T-Shock. It returns none under the applicant name Pagani either. The FDA's device registration and listing database returns no entry under either name. Those searches cover the product name and the maker's name as they are normally written. A US importer trading under some other company name would not show up under either.
CoolSculpting's paperwork is the opposite of thin. Its FDA category was created for it by a De Novo authorisation, DEN090002, decided 24 August 2010, covering the flanks alone. Every body area since has been added by a separate 510(k) against the company's own earlier clearance. Abdomen came in 2012, thigh in 2014, under the chin in 2015. Bra fat, back fat and banana roll followed in 2016, with the upper arm later that year and under the jawline in 2018. The chain runs through to K233732 on 12 September 2024. A 510(k) clearance is a finding that a device is much the same as one already on the market. It is not proof that it works. But it does produce something a clinic can be held to: named areas, a body mass index limit, a stated target temperature and a stated cycle length.
No clearance found is not a finding that a device does nothing, and it is not an accusation. It means nobody has put this device in front of the FDA and shown it is equivalent to something already cleared for fat reduction. The practical result is that there is no labelling. No cleared body areas. No limits on who can be treated. No agreed temperature or duration. No listed reasons to avoid it, and no maker's safety document to read before you consent.
It also does not mean anything unlawful is happening in the room. FDA regulates what manufacturers claim, not the practice of medicine. Practitioners may lawfully use equipment as they judge fit. Where FDA does act is on claims. In a December 2023 warning letter to an overseas maker of fat-freezing and other aesthetic hardware, the agency's position was that claiming to "eliminate fat cells" is exactly what turns a product into a medical device that needs clearance.
And no published clinical study of the Pagani Cryo T-Shock could be located in the medical literature. That is a statement about this device under this name. Cryolipolysis as a technology has a large published record. That record was built on other machines, at documented temperatures, for documented lengths of time.
Every available description of the technology comes from clinic and distributor pages. No maker's instructions for use are posted publicly.
The device description in the FDA summaries states a target temperature held to within half a degree. The cycle stops on its own if the surface temperature runs more than 1 degree past that target.
What temperature the fat actually reaches, and for how long, has not been measured and published for this device. Nor has whether that is enough to kill fat cells.
Fat cells are more easily harmed by cold than skin, nerve, vessel and muscle. The cold inflames the fat lobules. The cells die over days and are cleared over the following months.
So there is no cleared indication text, no cleared body area, and no limit on who can be treated. Scope that to those two names. It is what the FDA database returns for them.
Under the chin and under the jawline are cleared separately, up to a body mass index of 46.2. CoolSculpting Elite is K212707, cleared 5 November 2021.
PubMed returns no clinical study of this device.
FDA's own pooled review of 4,792 cryolipolysis treatments gave a mean ultrasound fat-layer drop of 20.6%, or 3.9 mm. Study means ran from 10.3% to 25.5%. The single best independent number comes from a randomised split-body trial: about 14% by ultrasound at 12 weeks.
The treatment is comfortable, and warm-and-cold rather than sharply cold. That is the main thing people say they like about it. It is a description of the experience, not of a result.
It is poor at loose skin, at cellulite, and at anything spread out.
No published safety data exists for this device. So there is no record of what its side effects look like, or how often they happen. No published reports is not the same as no risk.
A review of 554 procedures called delayed pain arriving a few days later not uncommon. It lasted 3 to 11 days. Numbness is the common effect that lasts longest. In one FDA-reviewed study, 4 of 30 patients still had it past 12 weeks.
There is no studied protocol to compare a clinic's package against.
One multi-site practice reviewed 18,203 cycles. The median was 4 cycles and 1 session per patient. The mean was 5.6 cycles.
To hold a fat-reduction clearance in this category, a maker has to name the body areas it is claiming. FDA then has to agree the device is much the same as a cleared device that came before it. For cryolipolysis that has meant filing temperature and duration settings, bench data, and usually a clinical study.
That process is not a guarantee of benefit. For CoolSculpting it produced a set of clearances whose main endpoint was usually a photo test. Three blinded reviewers had to pick the "before" photograph out of a pair. That is a spot-the-difference test, not a measurement of fat. In the pivotal under-chin study of 60 people, run by the manufacturer, the rate was 91%, against a pre-set bar of 80%. The fat measurement was a secondary endpoint: 0.20 cm by ultrasound at 12 weeks.
What clearance does give you is text: An indication that names the body areas. A body mass index ceiling. A stated temperature and cycle time. A published list of reasons not to have it. And a category-level risk list that FDA itself wrote: discomfort, pain, tenderness, thermal injury, whole-body response to cold, inflammation and use error. When there is no clearance, none of that exists. A clinic's claims are then answerable to nothing but the clinic.
Three things, in practice.
You cannot check the claim against a label: If a page says a device is "clinically proven" or "FDA registered", ask for the clearance number and look it up. Registration of a facility, listing of a product, and clearance of a device for a specific claim are three different things. Only the last one carries an indication.
There is no comparison group for side effects: Cryolipolysis has a documented set of side effects: numbness, long-lasting pain, skin darkening, cold panniculitis, and rare paradoxical adipose hyperplasia. That record exists because the treatment has been studied, reported and watched for fifteen years. A device with no published study and no clearance has no such record. That is a gap in knowledge, not a clean bill of health.
Nothing sets the dose: Cryolipolysis works by holding tissue at a set temperature for a set time. With a probe moved over the skin by hand, the exposure depends on the operator. For this device, nobody has published what tissue temperature is reached, or for how long.
FDA's page for patients on non-invasive body contouring was last updated 15 October 2025. It is blunt about the whole category: "Non-invasive body contouring does not treat obesity or improve your health. It will not result in weight loss or contribute to the health benefits associated with weight loss." CoolSculpting's maker says the same in its own safety information. The procedure "is not a treatment for weight loss".
The pooled data agrees, awkwardly. One 2025 meta-analysis of cryolipolysis reports a drop in body mass index. In the same dataset it finds no real change in weight: a mean of 1.81 kg, with a confidence interval crossing zero, p = 0.09. Those two numbers cannot both be describing a treatment effect. This is roughly how "cryolipolysis reduces BMI" got onto the internet.
This one belongs to cryolipolysis, and it is the reason to take the cold seriously as a real treatment rather than a spa service.
Paradoxical adipose hyperplasia is a firm, clearly edged, usually painless swelling of a treated area, in which the fat ends up larger than before. It usually appears two to six months after treatment, does not clear up by itself, and correction is surgical. Published incidence estimates disagree by about a hundredfold, largely because some count cycles and some count patients.
Whether an unmeasured cold exposure carries any similar risk is unknown, because it has not been studied.
Ask which device, made by whom, and what its FDA clearance number is: A clinic offering a cold body treatment may be running any of several machines, and they are not interchangeable. If no number is offered, that is your answer. You can still decide to go ahead - just do it knowingly.
Disclose cryoglobulinaemia, cold agglutinin disease or paroxysmal cold haemoglobinuria: These three rule out CoolSculpting completely in its safety information. All three are blood disorders in which cold destroys red blood cells. That logic does not stop applying because a different machine is being used.
Mention a further list of conditions: Cold urticaria, Raynaud's disease, pernio or chilblains. Poor circulation or reduced feeling in the area. Nerve pain conditions, bleeding disorders or blood thinners. Recent surgery or scarring in the area. An implanted device such as a pacemaker. And any hernia in or near the treatment site. These are the labelled precautions for cryolipolysis. For a device with no published labelling, they are the sensible starting list.
Fever or chills after treatment
Redness spreading outward from a treated area, visibly worse hour by hour
Pus or discharge from treated skin
These are signs of a spreading infection and need urgent care the same day.
A firm, well-defined lump appears in a CoolSculpting-treated area two to six months later, above all if it matches the shape of the applicator
Numbness in a treated area is still there beyond about three months
Pain is rising after the first few days rather than settling
Blistering, crusting or an open patch appears on treated skin
The skin over a treated area darkens a lot in the weeks afterwards
An area starts to look dented or hollow next to the other side